Amended Current Report Filing (8-k/a)
October 26 2021 - 10:43AM
Edgar (US Regulatory)
0001642159 true 8-K/A 0001642159
2021-10-20 2021-10-20 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC
20549
AMENDMENT
NO. 1 TO FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of
report (Date of earliest event reported):
October 20, 2021
SIGYN THERAPEUTICS, INC. |
(Exact Name
of Registrant as Specified in Its Charter) |
Delaware |
|
333-204486 |
|
47-2573116 |
(State or
other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2468 Historic Decatur Road, |
|
|
Suite 140
San Diego,
California
|
|
92106 |
(Address of
principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
619.368.2000
Prior address and phone number:
8880
Rio San Diego Drive |
|
|
Suite
800
San Diego,
CA.
|
|
92108 |
(Address of
principal executive offices) |
|
(Zip
Code) |
(213)
457-3772
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title of
each class |
|
Trading
Symbol |
|
Name of
each exchange on which registered |
None |
|
None |
|
None |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
As used
herein, the terms, “we,” “us,” “our,” and the “Company” refers to
Sigyn Therapeutics, Inc., a Delaware corporation and its
subsidiaries, unless otherwise stated.
CAUTIONARY NOTE
REGARDING FORWARD-LOOKING STATEMENTS
This Form
8-K and other reports filed by Sigyn Therapeutics, Inc. (“Sigyn” or
the “Company”) from time to time with the Securities and
Exchange Commission (collectively, the “Filings”) contain or
may contain forward looking statements and information that are
based upon beliefs of, and information currently available to, the
Company’s management as well as estimates and assumptions made by
the Company’s management. When used in the filings the words
“anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”,
“plan” or the negative of these terms and similar expressions as
they relate to the Company or Company’s management identify forward
looking statements. Such statements reflect the current view of the
Company with respect to future events and are subject to risks,
uncertainties, assumptions and other factors relating to the
Company’s industry, the Company’s operations and results of
operations and any businesses that may be acquired by the Company.
Should one or more of these risks or uncertainties materialize, or
should the underlying assumptions prove incorrect, actual results
may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.
Although the
Company’s management believes that the expectations reflected in
the forward looking statements are reasonable, the Company cannot
guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to actual results. The following discussion should be
read in conjunction with the Company’s pro forma financial
statements and the related notes filed with this Form
8-K.
Item 1.01
Entry Into a Material Definitive Agreement.
This Amendment No. 1 corrects a typographical error in the first
sentence of Item 1.01 which sentence is amended to read, in its
entirety: “On October 20, 2021, Sigyn Therapeutics, Inc. (the
“Company”) consummated, with accredited investors, the sale of
320,000 shares of Company common stock and warrants to purchase an
aggregate of 320,000 shares of the Company’s common stock for gross
proceeds totaling $400,000.”
Item
9.01. Financial Statements and Exhibits.
104 |
|
Cover Page Interactive
Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to
the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
SIGYN
THERAPEUTICS, INC. |
|
|
Date:
October 26, 2021 |
By: |
/s/ James
A. Joyce |
|
|
James A. Joyce, Chairman
and CEO |
Sigyn Therapeutics (PK) (USOTC:SIGY)
Historical Stock Chart
From Apr 2022 to May 2022
Sigyn Therapeutics (PK) (USOTC:SIGY)
Historical Stock Chart
From May 2021 to May 2022